EGFR and head and neck squamous cell carcinoma: Cetuximab, an anti-EGFR monoclonal antibody, is approved for advanced OSCC and HNSCC and offers a therapeutic option for EGFR-positive tumors, although its response rate remains limited to 10–20% [39].